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Abstract
Pathogenic variants in FBXL4 cause a severe encephalopathic
syndrome associated with mtDNA depletion and deficient oxidative
phosphorylation. To gain further insight into the enigmatic patho-
physiology caused by FBXL4 deficiency, we generated homozygous
Fbxl4 knockout mice and found that they display a predominant peri-
natal lethality. Surprisingly, the few surviving animals are apparently
normal until the age of 8–12 months when they gradually develop
signs of mitochondrial dysfunction and weight loss. One-year-old
Fbxl4 knockouts show a global reduction in a variety of mitochondrial
proteins and mtDNA depletion, whereas lysosomal proteins are
upregulated. Fibroblasts from patients with FBXL4 deficiency and
human FBXL4 knockout cells also have reduced steady-state levels of
mitochondrial proteins that can be attributed to increased mitochon-
drial turnover. Inhibition of lysosomal function in these cells reverses
the mitochondrial phenotype, whereas proteasomal inhibition has no
effect. Taken together, the results we present here show that FBXL4
prevents mitochondrial removal via autophagy and that loss of FBXL4
leads to decreased mitochondrial content and mitochondrial disease.
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Introduction
Mitochondrial diseases are a heterogeneous group of inherited meta-
bolic disorders characterized by deficient oxidative phosphorylation
(OXPHOS) that leads to a variety of secondary metabolic defects
and pleiotropic clinical phenotypes (Gorman et al, 2016). Mutations
that cause mitochondrial disorders can be localized to either nuclear
DNA or mtDNA and may affect a variety of mitochondrial processes
such as mtDNA expression, biogenesis of the OXPHOS system, mito-
chondrial protein import, or mitochondrial dynamics. Although a
given pathogenic mutation often is rare, the collective burden of
such mutations is substantial, making mitochondrial diseases the
most common form of inherited metabolic disorders.
In order to keep the mitochondrial population of the cell in shape,
several quality control mechanisms act on mitochondria. These
mechanisms include the cytosolic ubiquitin–proteasome system,
several intramitochondrial proteolytic systems, autophagic clearance
of damaged mitochondria, and the mitochondria-derived vesicle
pathway (Bragoszewski et al, 2017; Zimmermann & Reichert, 2017;
Pickles et al, 2018). Mutations in Parkin and PINK1 cause early-onset
forms of Parkinson’s disease, and the corresponding proteins have
been reported to be involved in mitochondrial protein control
(Hauser & Hastings, 2013; Moon & Paek, 2015; Hernandez et al,
2016), but their in vivo roles remain controversial (Lee et al, 2018;
Sliter et al, 2018). Apart from PARKIN, other ubiquitin ligases, such
as FBXO7, MARCH5, and HUWE1, have been related to mitochon-
drial quality control by directing proteins for proteasomal degrada-
tion or by triggering mitophagy (Chen et al, 2017; Di Rita et al, 2018;
Zhou et al, 2018). Recently, ubiquitination has also been reported to
occur in the inner mitochondrial membrane and this process may
possibly contribute to fine-tune metabolism according to the ener-
getic demand of the cell (Lavie et al, 2018).
FBXL4 is a nuclear gene that is implicated in control of mitochon-
drial function as biallelic mutations recently have been linked to
encephalopathy associated with an mtDNA maintenance defect
syndrome (Bonnen et al, 2013; Gai et al, 2013). The disease onset
varies from the neonatal period to a few years after birth, and
affected patients present a wide range of manifestations, including
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developmental delay, dysmorphology, lactic acidosis, generalized
hypotonia, and decreased mtDNA levels (Huemer et al, 2015; El-
Hattab et al, 2017). FBXL4 mutations are found in ~ 0.7% of all
mitochondrial patients and in ~ 14% of children with congenital
lactic acidosis, making it one of the most common causes of mito-
chondrial disease (Dai et al, 2017). Despite the high prevalence and
severe consequences of pathogenic FBXL4 mutations, the molecular
function of the FBXL4 protein has remained poorly understood
(Antoun et al, 2015; Huemer et al, 2015; Wortmann et al, 2015; Dai
et al, 2017; El-Hattab et al, 2017).
FBXL4 belongs to a family of F-box proteins, which typically
serve as substrate adaptors in so-called Skp1-cullin1-F-box (SCF) E3
ubiquitin ligase protein complexes (Skaar et al, 2013; Zheng et al,
2016). However, F-box proteins may also have SCF-independent
functions, e.g., as regulators of cellular proliferation, intracellular
trafficking, mitochondrial dynamics, and other processes (Nelson
et al, 2013; Zhou et al, 2018). Consequently, SCF-independent func-
tions of FBXL4 cannot be excluded, although it is suggested to be
part of an SCF complex (Van Rechem et al, 2011).
Previous studies have focused on using patient-derived fibrob-
lasts to characterize the molecular phenotype of FBXL4 mutations.
These studies have shown that loss of FBXL4 is associated with
decreased mtDNA levels, decreased levels of OXPHOS protein
components, reduced OXPHOS activity, and low oxygen consump-
tion (Bonnen et al, 2013; Gai et al, 2013), but the precise role of
FBXL4 in mitochondria is still unknown. Moreover, cytosolic roles
for FBXL4 acting as a component of a ubiquitin ligase complex have
been described both in mammalian cell lines and in fruit flies (Van
Rechem et al, 2011; Li et al, 2017).
Here, we describe an Fbxl4 knockout mouse and show that it
recapitulates important phenotypes present in patients with mito-
chondrial disease caused by FBXL4 mutations. Using proteomic
approaches, we demonstrate that there is a general decrease in mito-
chondrial proteins accompanied by an increase in lysosomal
proteins in Fbxl4 mouse knockout tissues as well as in fibroblasts
derived from patients with loss-of-function FBXL4 mutations.
Surprisingly, expression of nuclear genes encoding mitochondrial
proteins and mitochondrial translation remained unaffected in the
absence of FBXL4. We present data showing that the molecular
phenotype instead is explained by increased autophagic removal of
mitochondria, leading to a global decrease in cellular mitochondrial
content. Treatment with the lysosomal inhibitor ammonium chlo-
ride rescues mitochondrial protein stability in FBXL4 knockout
human cells, consistent with the hypothesis that increased autop-
hagy flux is an important pathophysiological event. In summary,
our results show that increased autophagic removal of mitochondria
plays an important role in mitochondrial diseases caused by muta-
tions in FBXL4. Further studies are needed to explore the therapeu-
tic potential of these findings, in particular whether inhibition of
autophagy may provide a strategy for treatment of affected patients.
Results
Fbxl4 knockout mice have high perinatal mortality
We generated mice with a conditional Fbxl4 knockout allele and
obtained heterozygous knockouts (Fbxl4+/; Fig 1A) after breeding
to b-actin-cre mice. We analyzed staged embryos at embryonic day
(E) 13.5 and found that Fbxl4/ embryos were recovered at near
the expected Mendelian frequency (Fig 1B) and had a normal gross
morphological appearance (Fig 1C). In contrast, very few homozy-
gous knockout (Fbxl4/) mice were recovered at weaning (Fig 1B)
pointing toward late embryonic or perinatal lethality. Chi-square
analysis of the data confirmed a significant difference in the geno-
type distribution in the mice compared with the expected Mendelian
ratios (P-value < 0.0001). Further analysis showed that there was
an increased frequency of dead pups after birth although the exact
frequency cannot be determined due to cannibalization by the
mother. These findings show that most Fbxl4/ pups die in the
neonatal period.
Patients with FBXL4 mutations display a significant reduction in
mtDNA content (Bonnen et al, 2013; Gai et al, 2013), and we there-
fore measured the relative mtDNA copy number by quantitative
real-time PCR (qRT–PCR). We found that homozygous knockout
(Fbxl4/) embryos at E13.5 had ~ 25% lower mtDNA content in
comparison with wild-type embryos (Fig 1D). However, this moder-
ate reduction in mtDNA copy number is unlikely to affect embryo
viability because heterozygous Tfam knockout mice are born at
Mendelian ratios despite having ~ 50% reduction in mtDNA copy
number (Larsson et al, 1998).
Surprisingly, the rare surviving Fbxl4/ animals looked appar-
ently normal until 8–12 months of age when a reduction in body
weight was noticed (Fig 1E and F). Most animals (~ 60%) also had
a hunch-back appearance at this age (Fig 1E), and ~ 40% of animals
had reduced movement, being apathetic or nervous when handled.
At 1 year of age, a significant weight difference was observed in
both males and females (Fig 1F). The absolute weights of heart,
liver, and kidney were normal or near normal in Fbxl4/ females
and males (Fig 1G–I), whereas organ-to-body weight ratios were
▸Figure 1. Fbxl4 knockout mice that are viable at the postnatal stage display mild growth defects.A Strategy to generate Fbxl4 knockout mice. Exon IV was targeted by loxP sites (orange arrows) and removed after Cre recombination. Black arrows indicate Frt sites.
B Genotype distribution in litters from heterozygous matings (Fbxl4+/ × Fbxl4+/) at embryonic stage 13.5 (E13.5) and of live animals at weaning. Data are presented
as a percentage. Embryos n = 79, weaned mice n = 339. Dashed lines indicate the expected Mendelian ratios. Chi-square test versus expected Mendelian ratios;
***P < 0.001.
C Representative images of wild-type (+/+), heterozygous knockout (+/), and homozygous Fbxl4 knockout embryos (/) at E13.5.
D Relative levels of mtDNA of Fbxl4 knockout (/) embryos and the corresponding wild-type (+/+) embryos at E13.5. Data represent mean  SEM, n = 5. Student’s
t-test; *P < 0.05.
E Representative images of male Fbxl4 knockout (/) and matched wild-type (+/+) animals at 1 year of age (left). A hunch-back phenotype was observed both in
male and in female knockout animals (right, indicated by arrow).
F–I Whole body (F), heart (G), liver (H), and kidney (I) weights of 1-year-old animals. Data represent mean  SEM, n ≥ 5 animals. Student’s t-test; *P < 0.05; **P < 0.01;
***P < 0.001; n.s., not significant (P ≥ 0.05).
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significantly increased for most organs (Fig EV1A–C). Histological
examination of organs of 1-year-old Fbxl4/ animals showed no
pathological alterations in the heart nor the kidney (Fig EV1D).
However, we observed infiltration of macrophages in the liver, con-
firmed by Iba1 staining (Fig EV1E), pointing to tissue damage and
degeneration. We did not observe differences in COX or sequential
COX/SDH reactivities in skeletal muscle sections (Fig EV1F).
Fbxl4 knockout mice have decreased levels of mtDNA and
mitochondrial proteins
Levels of mtDNA were significantly decreased in liver, kidney, and
brain but not in heart and skeletal muscle of Fbxl4/ mice at the
age of 1 year (Fig 2A). Also, the mtDNA-encoded transcripts were
significantly lower in all analyzed tissues, whereas the levels of
nuclear transcripts remained mostly unaffected (Fig 2B).
The decrease in mtDNA and mtDNA-encoded transcripts can
be due to a selective depletion of mtDNA or a general decrease
in mitochondrial content in the tissue. To investigate this ques-
tion, we determined the cellular content of mitochondrial proteins
and the protein content of isolated mitochondria by using
Western blot and mass spectrometry analyses (Figs 2C–F and
EV2A–F). The steady-state levels of selected mitochondrial
proteins, as determined by Western blotting, were strongly
decreased in whole liver homogenates of Fbxl4/ animals, irre-
spective of if they were encoded by mtDNA or nuclear DNA
(Fig 2C). Tandem mass tag (TMT)-based mass spectrometry anal-
ysis of liver tissue homogenate confirmed a global, pathway-inde-
pendent reduction in mitochondrial proteins, whereas there was
an enrichment of lysosomal proteins, such as cathepsins (Ctsb,
Ctsc, Ctsd, Ctsl) and other hydrolases (Fig 2E and F, and Dataset
EV1). A total of 83 proteins showed significant changes, 57 of
which were downregulated and 26 upregulated in homogenate
from whole Fbxl4/ liver (Fig 2E and Dataset EV1). In contrast,
label-free, global proteomic analyses of isolated mitochondria
from liver, kidney, and heart showed only mild changes in the
proteome affecting, e.g., amino acid degradation pathways and
propanoate metabolism, consistent with mild metabolic derange-
ment in Fbxl4/ mitochondria. Importantly, we found no
changes in the expression of nuclear-encoded proteins controlling
mtDNA maintenance. Analysis of selected proteins by Western
blots confirmed the results from proteomics (Fig EV2B, D and F).
The proteomic changes displayed a strong tissue specificity with
only six proteins (Pgam5, Grhpr, Acsm5, Spr, Nmat3, and Nit2)
consistently changed in mitochondria from all three analyzed
tissues (Fig EV2G and Dataset EV2). Kidney and liver, the most
affected organs, had 52 commonly changed proteins, mostly
belonging to mitochondrial metabolic enzymes and not related to
mtDNA maintenance and expression (Dataset EV2).
We proceeded to assess the assembly of OXPHOS complexes in
Fbxl4 knockouts by resolving respiratory chain complexes from liver
mitochondria with blue native polyacrylamide gel electrophoresis
(BN–PAGE) followed by in-gel enzyme activity staining for
complexes I and IV, and Coomassie staining (Fig EV2H). Despite
reduced amounts of the OXPHOS complexes, consistent with
reduced steady-state respiratory chain protein levels, no aberrantly
assembled or unassembled subcomplexes were observed. In agree-
ment with the BN–PAGE data, spectrophotometric measurement of
OXPHOS complex enzyme activities in liver mitochondria did not
show major alterations, except a mild, but significant, decrease in
complex IV activity (Fig EV2I). Overall, these results are in line with
the hypothesis that the mitochondrial dysfunction in Fbxl4/
animals is predominantly due to reduced cellular mitochondrial
content likely through turnover by lysosomes.
Alterations in patient fibroblasts are similar to the changes in
knockout animals
To investigate whether the findings in Fbxl4/ mice are relevant for
the human disease, we characterized fibroblasts obtained from skin
biopsies of three patients homozygous for recessive FBXL4 muta-
tions (Fig 3A) and three age-matched healthy controls. Patient 1 and
Patient 2 have been published previously (Bonnen et al, 2013) and
harbor homozygous FBXL4 mutations, p.Arg435* and p.Gln519*,
respectively (GenBank Accession Number: NM 012160.3). Patient 3
was diagnosed at Karolinska University Hospital and is a compound
heterozygote for two independently segregating FBXL4 mutations,
p.Arg22* on one allele and p.Arg206* on the other allele.
FBXL4-deficient fibroblasts had lower mtDNA content compared
with age-matched control fibroblasts (Fig 3B), in line with previ-
ously published findings (Bonnen et al, 2013; Gai et al, 2013). The
levels of mitochondrial proteins were also significantly lower in
patient-derived fibroblasts compared with controls, both for
mtDNA- and nuclear-encoded proteins (Fig 3C and D). Importantly,
▸Figure 2. Fbxl4 knockout mice have reduced amounts of mtDNA and mitochondrial proteins.A Relative levels of mtDNA in tissues of 1-year-old Fbxl4 knockout mice determined by quantitative real-time PCR (normalized to controls). Data are presented as
mean  SEM, n = 6 for controls and n = 8 for knockout animals. Student’s t-test; **P < 0.01; ***P < 0.001.
B Transcript levels in indicated tissues of 1-year-old Fbxl4 knockout mice determined by quantitative real-time PCR. Relative mRNA levels in control animals were set as
1 (dashed line). Data are presented as mean  SEM, n = 6 for controls and n = 8 for knockout animals. Student’s t-test; *P < 0.05; **P < 0.01; ***P < 0.001.
C Western blot analysis of protein steady-state levels in liver protein extracts from wild-type (Fbxl4+/+) and Fbxl4 knockout (Fbxl4/) animals.
D Quantification of the Western blot in (C). Signal normalized to the average of controls and presented as mean  SEM, n = 4 for both controls and knockout animals.
Student’s t-test; **P < 0.01; ***P < 0.001.
E Quantitative TMT-based proteomic analysis of wild-type and Fbxl4 knockout liver tissue protein extracts. Proteins from three control and three Fbxl4 knockout liver
protein extracts were TMT-labeled, quantified, and analyzed separately as described in Materials and Methods; the data from control and knockout animals were
averaged after the analysis and presented as log10 of the adjusted P-value versus log2 fold change (logFC). Mitochondrial proteins were selected according to mouse
MitoCarta 2.0 (Calvo et al, 2016) and highlighted in red; lysosomal proteins were selected according to hLGDB database (Brozzi et al, 2013) and highlighted in yellow.
F Enrichment analysis of lysosomal and mitochondrial proteins according to the logFC median of each group of proteins. Data are presented as 25–75 percentile box
with the indicated median, and whiskers representing the  1.5× inter-quartile range. Proteins included in each group: total = 1,523, lysosome = 50,
mitochondria = 324.
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levels of mtDNA-encoded transcripts were decreased, whereas
levels of nuclear transcripts encoding mitochondrial proteins were
present at normal levels (Fig 3E). The global reduction in mitochon-
drial protein levels is thus explained by post-transcriptional events
rather than by differences in nuclear gene expression.
Tandem mass tag-based quantitative proteomic analysis of
patient fibroblasts showed a clear trend with downregulation of
many mitochondrial proteins (Fig 3F), which is in good agreement
with the Western blot results (Fig 3C). Importantly, FBXL4-deficient
fibroblasts have a mild increase in levels of lysosomal proteins
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(Fig 3F and Dataset EV3) similar to the observation in knockout
mouse tissues (Fig 2E and F). No alterations in lysosomal morphol-
ogy were observed in confocal images of Lamp2-stained cells
(Fig EV3A). Moreover, we did not observe any significant change in
LysoSensor Green DND-189 fluorescence intensity (Fig EV3B).
Based on the observation of increased levels of lysosomal proteins
in mouse liver and patient fibroblasts lacking FBXL4 (Figs 2E and F,
and 3C and D) concomitant with unaffected lysosomal pH
(Fig EV3B), we conclude that increased lysosomal mass is increas-
ing mitochondrial turnover.
These findings point toward a conserved mechanism whereby
loss of FBXL4 in humans and mice leads to low levels of mitochon-
drial proteins, as demonstrated by the correlation of both proteomic
datasets (Fig 3G). The increase in levels of lysosomal proteins
induced by loss of FBXL4 was more marked in mouse tissues than
in cultured human fibroblasts (Fig 3G). To summarize, the overall
molecular phenotypes in whole tissue/cell extracts of FBXL4-defi-
cient mice and human fibroblasts showed many similarities with
low mtDNA levels, low levels of mitochondrial proteins, and
increased levels of lysosomal proteins.
Decreased protein stability in FBXL4 knockout cells
We generated an FBXL4 knockout RKO cell line by CRISPR/Cas9-
mediated gene disruption to get further insights into the role of
FBXL4 in a defined cell culture system. The resulting clone had a
20-bp-long deletion in exon 4 of the FBXL4 gene, leading to a
frameshift mutation and a stop codon in the open reading frame
(Fig 4A).
The levels of mitochondrial proteins were reduced in the FBXL4
knockout cell line, similar to the findings in FBXL4 mutant patient
fibroblasts (Fig 4B). To distinguish whether the altered levels of
mitochondrial proteins were due to alterations in their biogenesis or
degradation, we performed 35S labeling to study protein synthesis
followed by a 16- to 24-h chase to monitor protein stability (Fig 4C).
Mitochondrial translation was not affected in the knockout cell line,
whereas the amounts of labeled products were significantly reduced
after a 24-h chase, indicating an increased turnover of the newly
synthesized proteins in the absence of FBXL4.
Given that FBXL4 is an F-box protein suggested to play a role in
proteasomal degradation of proteins, we investigated whether inhi-
bition of proteasomal activity could rescue the observed phenotype.
To this end, we performed 35S labeling of cellular translation prod-
ucts and added the proteasomal inhibitor epoxomicin during the
chase phase of the experiment. Epoxomicin treatment increased the
differences in protein stability between wild-type and knockout cells
and thus promoted increased mitochondrial protein turnover
(Fig 4D). In contrast, treatment with the lysosomal inhibitor ammo-
nium chloride rescued the phenotype seen during the chase part of
the cellular in vitro translation experiment (Fig 4D).
Further analyses showed that LC3-II, p62/SQSTM1, and ubiquitin
conjugates accumulated to the same extent in both wild-type and
FBXL4 KO cells after treatment with the lysosomal inhibitor NH4Cl,
as well as after treatment with the proteasomal inhibitor epoxomicin
(Fig 4E and F).
Fibroblasts from FBXL4-deficient patients show
increased mitophagy
In order to further investigate the increased mitochondrial turnover
in the different patient fibroblast lines, we introduced a mito-QC
construct using a retroviral vector. Mito-QC is a GFP-mCherry
construct targeted to the mitochondria that allow the in vivo analy-
sis of mitophagy (Allen et al, 2013; McWilliams et al, 2016). In the
mitochondria, both proteins are fluorescent, but upon internaliza-
tion in the lysosome the low pH quenches GFP fluorescence but not
mCherry.
We analyzed patient fibroblast and a control line using confocal
microscopy and observed a mild but significant increase in the
number of mitolysosomes/cell area (lm2) in the patient lines when
compared to the control line expressing mito-QC (Fig 5A and B).
These results support the conclusion that pathogenic FBXL4 variants
lead to an increased mitochondrial turnover and, consequently,
mitochondrial dysfunction.
Next, we explored the autophagic flux in the patient fibroblast
lines by monitoring LC3 conversion and p62 protein levels. We grew
the cells in medium without FBS for 3 h and thereafter added NH4Cl
to block lysosomal function. As observed in the FBXL4 KO cells, no
differences were found in the LC3-II or p62 levels between control
and patient fibroblast lines (Fig EV4A–D). The findings indicate
normal autophagic flux and suggest that the increased mitochon-
drial turnover is dependent on an alternate pathway not involving
LC3 conversion. We also checked the accumulation of ubiquitin,
p62, and LC3 in sucrose-purified mitochondria (Fig EV4E and F).
◀ Figure 3. Mitochondrial alterations observed in FBXL4 patient-derived fibroblasts are consistent with the changes in knockout mice.A Schematic representation of the human FBXL4 protein with amino acid positions of mutations found in patients (P1, P2, and P3). Relative positions of the F-box,
leucine-rich repeat (LRR), and antagonist of mitotic exit network protein 1 (AMN1) domains are shown.
B Relative mtDNA content in fibroblasts from patients and controls as determined by qRT–PCR using an ND6 probe and normalized to nuclear genomic DNA content
using an 18S probe. Individual values are presented for each sample, as well as their mean  SEM values.
C Steady-state protein levels in three control and three FBXL4 patient-derived fibroblasts analyzed by Western blotting.
D Quantification of the Western blot in (C). Signals from the control and FBXL4-mutated cells were considered as biological replicates, normalized to the average of
controls, and displayed as mean  SEM (n = 3 for each). Student’s t-test; *P < 0.05; **P < 0.01; ***P < 0.001.
E Quantification of nuclear and mitochondrial transcript levels in control and patient fibroblasts. The results from control and patient cells were averaged, normalized
to controls, and displayed as mean  SEM (n = 3 biological replicates for each condition).
F Quantitative TMT-based proteomic analysis of control and patient fibroblasts. Proteins from three control and three patient fibroblast cell lines were TMT-labeled,
quantified, and analyzed separately as described in Materials and Methods; the data from control and patients were averaged after the analysis and presented as
log10 of the adjusted P-value versus log2 fold change (logFC). Mitochondrial proteins were selected according to human MitoCarta 2.0 (Calvo et al, 2016) and
highlighted in blue; lysosomal proteins were selected according to hLGDB database (Brozzi et al, 2013) and highlighted in yellow.
G Log2FC correlation analysis of mouse liver proteomic dataset and fibroblast proteomic dataset. Proteins with a log2FC > 0.5 are highlighted in black, and lysosomal
proteins are highlighted in yellow.
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No significant changes were found, supporting the suggestion of
activation of an alternate pathway for mitochondrial turnover in the
absence of Fbxl4.
In summary, we conclude that the increased mitochondrial
protein turnover seen in FBXL4 deficiency is due to increased
lysosomal degradation, likely via an alternative autophagy
◀ Figure 4. Lysosomal degradation of mitochondrial proteins is increased in FBXL4 knockout cells.A Genomic DNA sequence from FBXL4 knockout (KO) and wild-type (WT) RKO cells was compared to the NCBI reference FBXL4 coding sequence (CDS)
NM_001278716.2 and showed a frameshift-causing deletion in the knockout cells.
B Steady-state protein levels in wild-type (WT) and FBXL4 knockout (KO) RKO cells.
C (Upper panel) Pulse-chase labeling of mitochondrial translation products in wild-type (WT) and FBXL4 knockout (KO) cells. The cells were incubated for 1 h with a
35S methionine–cysteine labeling mix in the presence of anisomycin to inhibit cytosolic translation (pulse). After removal of the medium, the cells were incubated in
complete growth medium without inhibitors and labeled amino acids for 16 or 24 h (chase). A representative experiment of four biological replicates is shown. A
Coomassie-stained part of the gel is shown as loading control. (Lower panel) Quantification of the MTCO1-ND4 signal presented as mean  SEM; n = 4 biological
replicates; Student’s t-test; *P < 0.05.
D (Upper panel) Mitochondrial translation products were labeled in wild-type (WT) and FBXL4 knockout (KO) RKO cells for 60 min as in (C), followed by 24-h chase in
the presence of 5 lM epoxomicin (epoxo) or 20 mM ammonium chloride (NH4Cl). A representative experiment of n ≥ 3 biological replicates is shown. A fragment of
the Coomassie-stained gel is shown as loading control. (Lower panel) Quantification of the ND4-MTCO1 signal. n ≥ 3 biological replicates; data are presented as
mean  SEM. Student’s t-test; *P < 0.05.
E, F Steady-state levels of indicated proteins in wild-type and FBXL4 knockout RKO cells treated with NH4Cl (E), or epoxomicin (Epoxo, F).
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Figure 5. Mito-QC expression in patient fibroblasts shows increased number of mitolysosomes.
A Confocal images from the mito-QC-expressing fibroblast lines. Scale bar 25 lm.
B Quantification of the mitolysosomes/cell area (lm2) using the mito-QC counter plugin for ImageJ (Montava-Garriga et al, 2020). At least three technical replicates for
each line and n > 15 cells analyzed for each technical replicate. Data are presented as 25–75 percentile box with the indicated median and whiskers representing
5–95 percentile interval. Non-parametric Mann–Whitney test; ***P < 0.001.
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pathway, and is not explained by increased proteasomal activity.
Furthermore, inhibition of lysosomal function rescues the mito-
chondrial protein stability phenotype in FBXL4 deficiency,
suggesting that decreasing autophagy may be a strategy for the
treatment of affected patients.
Discussion
The pathophysiology of human FBXL4 deficiency causing an
encephalopathic syndrome associated with mtDNA depletion has
remained enigmatic. Here, we present evidence that FBXL4 acts as a
regulator preventing excessive turnover of mitochondria via lyso-
somes. We have characterized Fbxl4 knockout mice, FBXL4-defi-
cient patient fibroblast, and a human FBXL4 knockout cell line and
report several lines of evidence showing that loss of FBXL4 leads to
increased mitochondrial turnover via lysosomes.
Quantitative proteomics showed an overall decrease in mito-
chondrial content and an increase in lysosomal proteins both in
mouse tissues and in human fibroblasts lacking FBXL4. These
results led us to hypothesize that mitochondrial content was
decreased due to increased lysosomal degradation. This assump-
tion was supported by 35S labeling experiments, which showed
that mitochondrial protein stability in FBXL4 knockout cells was
reduced but could be rescued by inhibiting lysosomal hydrolases
with ammonium chloride. In further support of the hypothesis,
the mito-QC expression in patient fibroblasts showed an
increased number of mitolysosomes consistent with increased
mitochondrial turnover. However, the levels of LC3-II and also
p62, a global autophagy marker (Calvo-Garrido et al, 2019),
were similar in wild-type and FBXL4 knockout cells, also there
was no difference in levels of these proteins in control and
FBXL4 mutant human fibroblast lines. This finding can be
explained by an alternative autophagy pathway that is indepen-
dent of LC3. Such a pathway has been reported in Atg5 knock-
out mice and is dependent on the Rab GTPase, Rab9a (Kuma
et al, 2004). This pathway involves the participation of vesicles
from the trans-Golgi that engulf the cargos for subsequent fusion
with lysosomes (Kuma et al, 2004). There is increasing evidence
that Rab GTPases can play an important role during autophagy
and several members of this protein family have been related to
different steps in the autophagy process (Ao et al, 2014). Inter-
estingly, a slight increase in different Rab GTPases was observed
in both mouse and human fibroblasts lacking FBXL4, including
Rab9a in the case of human fibroblasts, which lends support to
the hypothesis of the existence of an alternate autophagy path-
way driven by this group of proteins. Another option that
cannot be excluded is a role for the MDV pathway which is also
independent of LC3 conversion (Sugiura et al, 2014).
As we did not observe changes in the conversion of LC3-I to
LC3-II, we assume that the classical pathway for autophagic flux
in FBXL4-deficient cells is not affected. Instead, an alternate
autophagy pathway may be upregulated leading to increased
mitochondrial removal. This model seemingly contradicts the
proposed role of FBXL4 as an F-box protein in the SCF complex.
One possible explanation for this apparent discrepancy implies
an important role for FBXL4 in mitochondrial quality control as
a substrate-recognizing subunit of the ubiquitin ligase complex.
Consistent with this model, the absence of FBXL4 would lead to
accumulation of aberrant mitochondrial proteins that could affect
mitochondrial function and thus increase the degradation of
mitochondria by the lysosome. However, there is no evidence
showing the presence of the SCF complex in mitochondria and
it is therefore unlikely that ubiquitination could happen in the
mitochondrial intermembrane space (IMS) via FBXL4. Recently,
it has been reported that ubiquitination could occur in the inner
mitochondrial membrane, but the ubiquitin ligases or complexes
catalyzing this reaction have not been identified (Lavie et al,
2018). Another possibility, although perhaps also unlikely, is that
FBXL4 could recognize unfolded or damaged proteins in the IMS
and promote their export to the cytosol for degradation. A some-
what similar mechanism has been shown in yeast, in which
unfolded proteins can be retro-translocated from the IMS to the
cytosol through the TOM complex and further degraded by the
ubiquitin–proteasomal system in the cytosol (Bragoszewski et al,
2015).
The phenotypes of Fbxl4/ mice agree with the alternate autop-
hagy pathway model. The finding that Fbxl4/ embryos are present
at Mendelian ratios and develop normally until E13.5 despite having
somewhat lower mtDNA levels argues that the mitochondrial
phenotype is not the leading cause of the perinatal death. It should
be pointed out that neonatal lethality has been reported in many
autophagy-deficient animals, e.g., Atg3, Atg5, Atg7, and Atg12
knockouts (Kuma et al, 2004, 2017; Mizushima & Levine, 2010).
Interestingly, Atg4b knockout mice were reported to be born at non-
Mendelian ratios, but developed almost normally after birth,
demonstrating a striking similarity to the Fbxl4/ phenotype (Read
et al, 2011). Although Fbxl4 knockout animals are not autophagy-
deficient, we assume that increased mitophagy flux at birth could
imbalance the overall autophagic states of the cell leading to mito-
chondrial deficiency. The decreased mitochondrial content caused
by increased autophagic removal likely has a particularly deleteri-
ous impact in the neonatal period as it may prevent the crucial
metabolic switch from glycolysis to OXPHOS in newborn animals.
The few newborn FBXL4-deficient animals that survive this critical
period will develop a slowly progressive mitochondrial phenotype
much later in life.
In summary, the results we present here argue that the molecular
phenotypes in FBXL4-deficient patients are explained by a global
decrease in mitochondrial content and not by a specific role for
FBXL4 in mtDNA maintenance or biogenesis of the OXPHOS
complexes. Importantly, the finding that inhibition of lysosomal
function can rescue molecular phenotypes in FBXL4-deficient cells
suggests that manipulation of mitochondrial clearance by autophagy
may be utilized as a future strategy to develop treatments of affected
patients.
Materials and Methods
Fbxl4 knockout mice
Fbxl4 knockout mice were generated by Taconic Artemis by target-
ing the gene in embryonic stem cells derived from C57BL/6N using
a vector from the C57BL/6J RPCI-23 BAC library. To generate the
Fbxl4 knockout allele, exon 4 was flanked by loxP sites, and a
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puromycin resistance (PuroR) cassette flanked by Frt sites was also
introduced as a selection marker. The puromycin resistance cassette
was removed by crossing Fbxl4+/loxP-Puro mice with mice expressing
Flp recombinase. Fbxl4+/loxP mice were thereafter mated with mice
ubiquitously expressing Cre recombinase (b-actin-cre) to generate
heterozygous Fbxl4 knockouts. Finally, intercrosses of heterozygous
knockout animals were performed to generate Fbxl4 knockout
animals (Fbxl4/). Animals were housed in standard ventilated
cages at 12-h light/dark cycle and fed with a normal chow diet ad li-
bitum. For isolation of tissues, animals were sacrificed by cervical
dislocation and dissected immediately. Isolated organs were snap-
frozen in liquid nitrogen and stored at 80°C. Animal studies were
approved by the animal welfare ethics committee and performed in
compliance with European law.
Histology
For heart, kidney, and liver microscopy analyses, tissues were fixed
in 4% PFA, dehydrated, and paraffin-embedded. Sections of 5 lm in
thickness were mounted on glass slides, de-paraffinized with
xylene, and stained with hematoxylin and eosin.
Immunohistochemical analysis
Liver sections were de-paraffinized with xylene and rehydrated by
successive incubations in ethanol 100, 95, and 70% and water.
Thereafter, slides were incubated in 10 mM sodium citrate buffer
(pH 6) at sub-boiling temperature for 10 min and cooled at room
temperature for 30 min. Before staining, slides were washed three
times with water and incubated in 3% hydrogen peroxide for
10 min to quench endogenous peroxidase activity and washed twice
in water. Thereafter, slides were blocked in 5% goat serum in TBST.
Iba1 primary antibody (Wako) was used to detect Iba1 expression.
Later, we used the VectaStain ABC HRP Kit (Vector Labs) and
diaminobenzidine to detect immunoreactivity. Finally, slides were
counter-stained with hematoxylin, dehydrated, and mounted for
bright-field microscopy.
Sequential COX/SDH histochemistry
COX/SDH histochemistry was performed as previously described
(Filograna et al, 2019). Briefly, quadriceps from wild-type and
FBXL4 knockout animals were washed in PBS and frozen in liquid
nitrogen-cooled isopentane. Sections, 14 lm, were mounted in poly-
lysine-coated glass slides and left air-dry briefly. Sections were incu-
bated for 45 min at 37°C in COX medium (100 lM cytochrome c,
4 mM diaminobenzidine tetrahydrochloride, catalase (20 lg/mL),
and 0.2 M phosphate buffer [pH 7]). Next, slides were washed in
PBS and incubated for 30 min at 37°C in SDH medium (130 mM
sodium succinate, 200 lM phenazinemethosulphate, 1 mM sodium
azide, 1.5 mM nitroblue tetrazolium, and 0.2 M phosphate buffer
[pH 7]). Finally, slides were washed in PBS, dehydrated in increasing
ethanol concentrations, and mounted for bright-field microscopy.
RNA extraction and gene expression analysis
RNA from mouse tissues or cells was extracted using TRIzol Reagent
(Invitrogen) following the manufacturer’s instructions. Total RNA
(1 lg) was converted to cDNA using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems), and 10 ng of cDNA
was used in each qPCR. These reactions were done with TaqMan
Universal MasterMix (Applied Biosystems) in a QuantStudio 6 Flex
(Applied Biosystems). Specific primers and probes were purchased
from Applied Biosystems (TaqMan gene expression assays). The
acquired data were analyzed with QuantStudio Real-Time PCR Soft-
ware (v1.1). Relative expression was calculated based on Ct values
for each gene normalized with the values obtained for housekeeping
genes (Actb, B2M, or 18S ribosomal RNA). All probes used in this
study are listed in Appendix Table S1.
DNA extraction and mtDNA quantification
Total DNA was isolated with standard phenol/chloroform and
proteinase K digestion protocol, and the concentration was
measured with Qubit DNA assay (Thermo Fisher Scientific). Quanti-
tative PCR was performed to quantify mtDNA, using 5 ng of total
DNA in each reaction. Specific probes for ND1 (mouse) or ND6 (hu-
man) were used to detect mtDNA, whereas the Actb probe (for
mouse) or the 18S ribosomal RNA probe (for human DNA) was
used to detect nuclear DNA. The relative mtDNA levels were calcu-
lated as the ratio of mtDNA/nDNA based on the obtained Ct values.
Cell culture
Mammalian cells were cultured in DMEM GlutaMax (Invitrogen)
medium supplemented with 10% fetal bovine serum (FBS) and 1×
PenStrep. Cells were grown in an incubator at 37°C in a 5% CO2
atmosphere. Patient fibroblasts lines 1 (p.Arg435*) and 2
(p.Gln519*) both harbor pathogenic, homozygous loss-of-function
FBXL4 mutations and were previously described in Bonnen et al,
2013 (S2 and S1, respectively, in the original report) (Bonnen et al,
2013). Patient fibroblast line 3 was obtained from a patient diag-
nosed at Karolinska University Hospital. Whole-genome sequencing
of this patient identified two previously unreported heterozygous
independently segregating stop mutations c.64C>T, p.Arg22* and
c.616C>T, p.Arg206* in the FBXL4 gene. The patient had widened
lateral ventricles of the brain on intrauterine ultrasound screening,
but showed no symptoms until 6 months of age when delayed
motor development and general hypotonia became evident. At this
age, the patient also had hyperlactatemia (p-lactate 6.5 mmol/l),
hypochromic anemia, and neutropenia. Organic acids in urine
showed elevated lactate, fumarate, and malate. There was decreased
ATP synthesis, and the activities of OXPHOS complexes I, I + III, II,
II + III and IV were reduced in isolated muscle mitochondria.
Control fibroblasts used in this study were obtained from age-
matched healthy individuals. Informed consent for research studies
was obtained for all subjects or their parents and for controls in
accordance with the Declaration of Helsinki protocols, the Depart-
ment of Health and Human Services Belmont Report, and approved
by the Regional Ethics Committee at Karolinska Institutet in Stock-
holm, Sweden.
The FBXL4 CRISPR knockout cell line was generated as previ-
ously described (Ran et al, 2013). Briefly, a DNA sequence encoding
a gRNA targeting FBXL4 exon 4 was cloned into the pX459v2 vector.
The RKO cell line (ATCC) was transfected with this vector using
Lipofectamine 3000 (Thermo Fisher Scientific) following the
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manufacturer’s recommendations. Transfected cells were selected
with puromycin, and obtained clones were sequenced to analyze
disruption of the FBXL4 gene.
Immunofluorescence
For Lamp2 immunofluorescence, cells were grown on glass cover-
slips. Coverslips were washed twice with PBS and fixed with 4%
PFA in PBS for 15 min. After, cells were incubated for 1 h in 1%
BSA, and 0.1% saponin in PBS. Cells were then incubated with
Lamp2 antibody (Abcam) in 1% BSA, and 0.1% saponin in PBS at
4°C overnight. Coverslips were washed two times with PBS and
then incubated with Alexa 568 anti-mouse secondary antibody for
1 h at room temperature. Finally, coverslips were stained with
DAPI, washed five times with PBS, and mounted using Prolong
Diamond Antifade Mountant (Life Technologies). The slides were
imaged in a Zeiss LSM700 confocal microscope.
LysoSensor Green fluorescence measurement
A total of 1,000 cells were plated in black p96 well plates and
allowed to attach. Thereafter, the medium was replaced with DMEM
with 2 lM LysoSensor Green DND-189 (Life Technologies) and cells
were incubated at 37°C for 30 min. Finally, cells were washed twice
with PBS and fluorescence was immediately measured in a Tecan
Infinite M200 Pro (Tecan). A total of five technical replicates were
done for each line, and in each technical replicate, at least three
wells per line were measured.
Mito-QC expression, imaging, and analysis
Mito-QC pBabe vector was kindly provided by Dr. Ian Ganley.
Transfection of fibroblast lines was done as previously described
(Allen et al, 2013). Cells stably expressing mito-QC were plated on
glass coverslips. Coverslips were washed with PBS and fixed with
4% PFA, and 200 mM HEPES-KOH pH = 7 for 15 min and washed
twice with PBS. Coverslips were mounted using Prolong Diamond
Antifade Mountant (Life Technologies) and imaged in a Zeiss
LSM700 confocal microscope. Obtained images were analyzed using
the ImageJ mito-QC counter semi-automated tool (Montava-Garriga
et al, 2020). Ratio threshold was set to 0.6, radius for smooth-
ing = 1, and standard deviation over mCherry mean intensity = 3.
At least three technical replicates were done for each line and > 15
cells analyzed in each replicate.
Preparation of pure mitochondrial fractions
Pure mitochondrial fractions were obtained as previously reported
(Ku¨hl et al, 2017). Briefly, crude mitochondrial fractions were
isolated from mouse liver, kidney, and heart using differential
centrifugation procedures. The crude mitochondrial pellets were
washed in 1xM buffer containing 220 mM mannitol, 70 mM sucrose,
5 mM HEPES ph = 7.4, and 1 mM EGTA, and thereafter, mitochon-
dria were purified in a Percoll gradient (12–19–40%) through
centrifugation in a SW41 rotor at 42,000 g at 4°C for 30 min in a
Beckman Coulter Optima L-100 XP ultracentrifuge. Mitochondria
were collected between 19 and 40% phases, and washed three times
with 1xM buffer. Mitochondrial pellets were frozen at 80°C.
SDS–PAGE, BN–PAGE, and Western blotting
The protein content of samples was measured by PierceTM BCA
Protein Assay Kit (Thermo Fisher Scientific), and equal protein
amounts were loaded on a gel. For SDS–PAGE, precast Bolt Bis-
Tris Plus Gels (Thermo Fisher Scientific) were used according to
manufacturer’s instructions. For Western blot analysis, the
gels were blotted and membranes probed with antibodies of
interest. Signal detection was done using HRP-coupled secondary
antibodies with enhanced chemiluminescence substrate (Bio-
Rad). A list of the used primary antibodies is provided in
Appendix Table S2.
BN–PAGE was performed using the NativePAGE system (Thermo
Fisher Scientific). In brief, 75 lg of mitochondria was solubilized in
solubilization buffer: 1% (w/v) digitonin, 20 mM Tris–HCl pH 7.4,
0.1 mM EDTA, 50 mM NaCl, and 10% glycerol (v/v). After 10 min
of incubation on ice, samples were centrifuged to eliminate non-
solubilized material and supernatant was mixed with 5% w/v
Coomassie Brilliant Blue G-250. Samples were separated in Native-
PAGE 3–12% Bis-Tris gels (Thermo Fisher Scientific) followed by
staining with Imperial Staining (Thermo Fisher Scientific) or in-gel
complex activity staining as described previously (Matic et al,
2018). For complex I staining, gels were soaked in Tris–HCl pH 7.4
buffer containing 0.1 mg/ml NADH and 2.5 mg/ml iodotetrazolium
chloride. For complex IV staining, gels were soaked in 50 mM phos-
phate buffer pH 7.4 with 0.5 M sucrose, 0.5 mg/ml 3,30-diamino-
benzidine tetrahydrochloride, 1 mg/ml cytochrome c, and 20 lg/ml
catalase.
Biochemical assessment of OXPHOS enzyme activities
For the determination of OXPHOS biochemical activities, we used
pure mitochondria isolated from liver. Protein concentration from
Percoll purified mitochondria fractions was determined using
PierceTM BCA Protein Assay Kit (Thermo Fisher Scientific) and
resuspended in a buffer containing 250 mM sucrose, 15 mM
magnesium acetate, 2 mM EDTA, 0.5 g/l BSA, and 15 mM potas-
sium dihydrogen phosphate pH = 7.2. Biochemical activities of
the respiratory chain complexes were determined spectrophoto-
metrically with standard methods as previously described (Wibom
et al, 2002).
35S labeling of translation products in cells
Labeling of mitochondrial translation products with 35S-methio-
nine was performed as described previously (Chomyn, 1996).
Cells were grown in 24-well plates, extensively washed with PBS,
and pre-incubated in Cys-Met-free DMEM medium (Gibco) for
20 min. Next, the cells were treated for 20 min with 100 lg/ml
anisomycin (Sigma) to block cytosolic translation, and 3.7 MBq of
35S-L-methionine and cysteine mix (PerkinElmer) was added to
the cells for 60 min to label newly synthesized mitochondrial
translation products. For the chase experiment, cells were exten-
sively washed with PBS and complete DMEM + FBS medium to
remove radioactive substances and anisomycin, and then grown
for 16–24 h. The radiolabelled translation products were resolved
by SDS–PAGE, and the gels were dried and exposed to phosphor
screens for radioactive signal detection.
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Protein extraction, proteolytic digestion, and chemical labeling
Cell pellet samples were suspended in a mixture of 0.1% Protea-
seMax (Promega), 4 M urea (Sigma-Aldrich), 50 mM ammonium
bicarbonate, and 10% acetonitrile (AcN), and were sonicated with a
VibraCell probe (Sonics & Materials, Inc.) for 1 min, with pulse 2/2,
at 20% amplitude. Following sonication in a water bath for 5 min,
extracts were vortexed and centrifuged for 5 min at 16,000 g. The
supernatants were thereafter transferred to new tubes, and protein
concentrations were determined in a 1:10 dilution with water yield-
ing 500–1,300 lg protein (mouse fibroblasts).
Tryptic digestion with an enzyme-to-protein ratio of 1:50 was
performed with 25 lg of each sample using a protocol including
reduction in 6 mM dithiothreitol at 37°C for 60 min, alkylation in
22 mM iodoacetamide for 30 min at room temperature in the dark,
and proteolysis over night at 37°C. Tryptic peptides were cleaned
with C18 HyperSep Filter Plate, bed volume 40 ll (Thermo Fisher
Scientific), and dried on a SpeedVac (miVac, Thermo Fisher Scien-
tific). Six of TMT10plex reagents (Thermo Fisher Scientific) in
100 lg aliquots were dissolved in 30 ll dry AcN, scrambled, and
mixed with the digested samples dissolved in 70 ll TEAB (resulting
final 30% AcN), followed by incubation at 22°C for 2 h at 550 rpm.
The reaction was then quenched with 12 ll of 5% hydroxylamine at
22°C for 15 min at 550 rpm. Finally, the labeled samples were
pooled and dried in a SpeedVac.
Enriched mitochondria were lysed in 6 M guanidinium chloride,
10 mM Tris–HCl, 40 mM chloroacetamide, and 100 mM Tris–HCl
by heating the solution at 95°C for 10 min, followed by repeated
cycles of sonication for 10 and 30 s and a 30-second pause on a
Bioruptor (Diagenode). Samples were centrifuged for 20 min at
20,000 g, and the supernatant was diluted 1:10 using 20 mM Tris–
HCl pH 8. Overnight digestion was done using 1 lg Trypsin Gold
(Promega) at 37°C. The supernatant was acidified with 50% formic
acid, and the solution was desalted using home-made StageTips
(Rappsilber et al, 2003).
Liquid chromatography–tandem mass spectrometry
Samples, 2 lg aliquots, were injected into a 50-cm-long C18 EASY
spray column (Thermo Fisher Scientific) installed in a nano-LC-1000
system online coupled to a Orbitrap Fusion mass spectrometer
(Thermo Fisher Scientific, Bremen, Germany). The chromatographic
separation of the peptides was achieved with the organic gradient as
follows: 2–26% AcN in 110 min, 26–35% AcN in 10 min, 35–95%
AcN in 5 min, and 95% AcN for 15 min at a flow rate of 300 nl/
min. Full mass scans were acquired in m/z 375–1,500 at resolution
of R = 120,000 (at m/z 200), followed by data-dependent HCD frag-
mentations from maximum 15 most intense precursor ions with a
charge state 2+ to 7+. The tandem mass scans were acquired with a
resolution of R = 60,000, targeting 5 × 104 ions, setting isolation
width to m/z 1.4, and normalized collision energy to 35%.
For label-free proteomic analysis, peptides were separated on a 25-
cm, 75-lm internal diameter PicoFrit analytical column (New Objec-
tive) packed with 1.9 lm ReproSil-Pur 120 C18-AQ media (Dr.
Maisch,) using an EASY-nLC 1200 (Thermo Fisher Scientific). The
column was maintained at 50°C. Buffer A and buffer B were 0.1%
formic acid in water and 0.1% formic acid in 80% acetonitrile.
Peptides were separated on a segmented gradient from 6 to 25%
buffer B for 135 min, from 25 to 31% for 20 min, and from 31 to 50%
buffer B for 20 min at 200 nl/min. Eluting peptides were analyzed on
a QExactive HF (Thermo Fisher Scientific). Peptide precursor m/z
measurements were carried out at 60,000 resolution in the 300–
1,800 m/z range. The ten most intense precursors with charge state
from 2 to 7 only were selected for HCD fragmentation using 25%
normalized collision energy. The m/z values of the peptide fragments
were measured in the Orbitrap at 30,000 resolution, using a minimum
AGC target of 8e3 and 55-ms maximum injection time. Upon fragmen-
tation, precursors were put on a dynamic exclusion list for 45 s.
Protein identification and quantification
Acquired raw data files were loaded in Proteome Discoverer v2.2
and searched against mouse or human SwissProt protein databases
(42,793 and 21,008 entries, respectively) using the Mascot 2.5.1
search engine (Matrix Science Ltd.). A maximum of two missed
cleavage sites were allowed for trypsin, while setting the precursor
and the fragment ion mass tolerance to 10 ppm and 0.05, respec-
tively. Dynamic modifications of oxidation on methionine, deamida-
tion of asparagine and glutamine, and acetylation of N-termini were
set. For quantification, both unique and razor peptides were
requested. The final quantitative data analysis was performed with
an in-house developed R script.
Label-free proteomic data were analyzed with MaxQuant version
1.6.1.0 (Cox & Mann, 2008) using the integrated Andromeda search
engine (Cox et al, 2011). Peptide fragmentation spectra were searched
against the canonical and isoform sequences of the mouse reference
proteome (proteome ID UP000000589, downloaded in September
2018 from UniProt). Methionine oxidation and protein N-terminal
acetylation were set as variable modifications; cysteine
carbamidomethylation was set as fixed modification. The digestion
parameters were set to “specific” and “Trypsin/P”. The minimum
number of peptides and razor peptides for protein identification was
1; the minimum number of unique peptides was 0. Protein identifi-
cation was performed at a peptide spectrum matches and protein false
discovery rate of 0.01. The “second peptide” option was on. Success-
ful identifications were transferred between the different raw files
using the “Match between runs” option. Label-free quantification
(LFQ) (Cox et al, 2014) was performed using an LFQ minimum ratio
count of two. LFQ intensities were filtered for at least two valid values
in at least one genotype, and missing values were imputed from a
normal distribution with a width of 0.3 and downshift of 1.8. Analysis
of the label-free quantification results was performed using R (R
Development Core Team, 2010). MitoCarta annotations were added
using the corresponding Gene names (primary) entry and the first of
the Gene names (synonym) entries of the oldest UniProt ID with the
highest number of peptides in the column “Protein IDs”. Only mito-
chondrial proteins, according to MitoCarta, were used for analysis.
Protein label-free intensities were normalized using vsn (Huber et al,
2002). Differential expression analysis was performed using the two-
sided moderated t-test from the limma package (Ritchie et al, 2015).
Exploratory data analysis was performed using ggplot and GGally.
Statistical methods
Data were statistically analyzed using GraphPad Prism 8 software
(except proteomics data as detailed above). Neither randomization
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nor blinding was implemented for animal studies and data analysis.
All data are presented by means  SEM. When two groups were
compared, a two-sided unpaired Student’s t-test was used, while a
one-way ANOVA and Tukey’s post hoc analysis were used for multi-
ple group comparison. Mito-QC data are presented as 5–95% percen-
tile boxplot, and non-parametric Mann–Whitney test was used for
statistical analysis. Genotype distribution in mice and embryos was
analyzed using chi-square test by comparing the obtained percentages
against the expected Mendelian percentages. P-values < 0.05 were
considered statistically significant. The exact number of replicates
and P-values for each figure are summarized in Appendix Table S3.
Data and software availability
The datasets produced in this study are available in the following
databases: Mass spectrometry datasets have been deposited to
the ProteomeXchange Consortium (Perez-Riverol et al, 2019):
PRIDE PXD18639 (http://www.ebi.ac.uk/pride/archive/projects/
PXD18639).
Expanded View for this article is available online.
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